Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges

Masterson, C. H.; Ceccato, A.; Artigas, A.; dos Santos, C.; Rocco, P. R.; Rolandsson Enes, S.; Weiss, D. J.; McAuley, D.; Matthay, M. A.; English, K.; Curley, G. F.; Laffey, J. G.

doi:10.1186/s40635-021-00424-5

Intensive Care Medicine Experimental

Table 2 Antiviral medications approved and recommended for treatment and chemoprophylaxis of influenza

From: Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges

Antiviral agent (trade name)	Activity against virus	Use	Safety and efficacy	References
Oseltamivir (Tamiflu®)	Influenza A and B	Treatment	Accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital	[139], [140], [141], [142]
Oseltamivir (Tamiflu®)	Influenza A and B	Chemoprophylaxis	Modest evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations	[141], [142]
Zanamivir (Relenza®)	Influenza A and B	Treatment	Decreases the risk of becoming symptomatic	[141], [143], [144], [145]
Zanamivir (Relenza®)	Influenza A and B	Chemoprophylaxis	Decreases the risk of becoming symptomatic	[141], [143], [144], [145]
Peramivir (Rapivab®)	Influenza A and B	Treatment	Reduces the time to alleviation of influenza symptoms	[146], [147]
Peramivir (Rapivab®)	Influenza A and B	Chemoprophylaxis	Reduces the time to alleviation of influenza symptoms	[146], [147]
Baloxavir (Xofluza®)	Influenza A and B	Treatment	Effective in alleviating influenza symptoms and reducing the viral load 1 day after initiation	[148], [149], [150], [151], [57], [152]
Baloxavir (Xofluza®)	Influenza A and B	Chemoprophylaxis		[148], [149], [150], [151], [57], [152]
Laninamivir (Inavir®)	Influenza A and B	Treatment	Inhibited the NA activities, reduces duration of symptoms	[153], [154], [155], [56], [156], [55]
Laninamivir (Inavir®)	Influenza A and B	Chemoprophylaxis	Inhibited the NA activities, reduces duration of symptoms	[153], [154], [155], [56], [156], [55]

Back to article page